Articles tagged with Prostate Cancer
Men with prostate cancer who played football for 12 weeks experienced significant gains in muscle mass and strength despite undergoing androgen deprivation therapy. The study also highlighted the positive social experiences and desire to remain active that came from playing football.
A survey of urologists and radiation oncologists found that most specialists view active surveillance as an effective treatment option but often fail to recommend it for their own patients. Instead, they tend to recommend treatments provided by their own specialty.
The American Cancer Society has released guidelines to support primary care of estimated 2.8 million men with a history of prostate cancer in the US. The guidelines outline posttreatment clinical follow-up care for long-term and late effects, including health promotion, surveillance for recurrence, and management of physical and psycho...
A new PSMA-based imaging agent, F-18 DCFBC PET/CT, has been developed to detect prostate cancer and monitor treatment response. The study shows the agent's effectiveness in detecting both castration-sensitive and castration-resistant forms of the disease.
A study published in Endocrine-Related Cancer has identified specific molecules in seminal fluid that can detect prostate cancer and predict its severity. The presence of these microRNAs, particularly miR-200b, shows promise as a prognostic tool for indicating treatment urgency and type.
The clinical validation study showed ProMark correctly identified low-risk disease with a sensitivity of 90% or better. The test provided additional independent prediction relative to standard risk-stratification systems, improving personalized treatment decisions for prostate cancer patients.
A Phase III clinical trial found that enzalutamide significantly reduced the risk of prostate cancer progression by 81 percent and improved overall survival by 29 percent. The treatment also helped prevent cancer spread to bones and delayed chemotherapy needs.
A behavior-altering enzyme commonly used in depression medications has been linked to prostate cancer growth. Suppressing this enzyme may reduce or eliminate prostate tumor growth and metastasis, offering a potential new treatment for men with metastatic prostate cancer.
A new study found that prostate cancer patients who underwent external beam radiation therapy were 70% more likely to develop rectal cancer and 40% more likely for bladder cancer. Survivors should be aware of symptoms such as pelvic pain, difficulty urinating, or blood in stool to monitor for potential secondary cancers.
Research suggests circumcision may reduce prostate cancer risk in certain populations, including Black men with a 60% lower risk. The study found no significant association between circumcision and prostate cancer risk for other ancestral groups.
A commercial epigenetic diagnostic test has been found to be accurate enough to exclude the need for repeat prostate biopsies in many men. The test analyzes DNA hypermethylation levels in specific genes and shows an 88% likelihood of no cancer when all three biomarkers are absent.
A recent study by Northwell Health demonstrates that magnetic resonance imaging (MRI) guided biopsies can detect prostate cancer more accurately, with a detection rate twice as high as previous data. The new targeted approach uses MRI and transrectal ultrasound fusion to identify clinically significant prostate cancer.
The Prolaris test accurately predicted 10-year death rates from prostate cancer and outperformed antiquated upgrading practice. In conservatively managed patients, the test differentiated high-risk disease from lower-risk disease.
A nationwide patient survey found that robot-assisted radical prostatectomy (RARP) is as safe as open surgery for Medicare patients over 65, but with higher costs. The study compared post-operative complications, blood transfusions, and hospital stays between RARP and open surgery.
A new UCLA study reveals that conventional biopsies may fail to detect aggressive cancers in men with low-risk prostate cancer, highlighting the need for a targeted biopsy approach. The findings suggest that the criteria for active surveillance should be re-evaluated to account for the risk inflation seen with targeted prostate biopsy.
Researchers have identified a new microRNA, hsa-miR-765, that suppresses expression of HMGA1 in prostate cancer cells, offering potential as a targeted therapy. The microRNA is activated by an FDA-approved anti-estrogen drug, fulvestrant.
Two new genes, FOXM1 and CENPF, linked to more aggressive prostate cancer have been discovered. A new approach in the treatment of these patients is being developed using computer algorithms and biomarkers.
A study by UCLA researchers found that treating older men with early-stage prostate cancer who also have other serious underlying health problems with aggressive therapies does not help them live longer. In fact, it can be detrimental and result in additional health issues such as impotence, urinary incontinence, and bowel problems.
Researchers discovered that FOXM1 and CENPF genes synergistically activate pathways associated with the most aggressive form of prostate cancer. The study identified these genes as a key driver pair in both mice and humans, and found that co-expression correlated with poor disease outcomes.
Men with low-risk prostate cancer who have low testosterone levels may be at increased risk of developing more aggressive disease. Low levels of free testosterone were significantly linked to an increased risk, suggesting a contradictory role for testosterone in prostate cancer progression.
A study found that vitamin D deficiency was associated with aggressive prostate cancer diagnosis and tumor progression in both European-American and African-American men. Lower levels of 25-hydroxyvitamin D (25-OH D) were linked to higher odds of having aggressive prostate cancer and faster disease progression.
A new study from Northwestern Medicine and the University of Illinois at Chicago finds that vitamin D deficiency is a predictor of aggressive forms of prostate cancer diagnosis in African-American and European-American men. Regular screenings for vitamin D deficiency could be crucial to prevent advanced tumor progression.
A novel electronic nose technique has been successfully used to discriminate between prostate cancer and benign prostatic hyperplasia in a proof-of-principle study. The eNose system demonstrated sensitivity and specificity comparable to traditional testing methods, such as prostate-specific antigen (PSA), with rapid and non-invasive re...
A new computational model simulates bone metastasis of prostate cancer and accurately predicts the impact of potential therapies on cancer cells and normal cells of the bone. The model was validated by comparing its predictions with tumor growth rates in mice, and identified critical players and events in the process of bone metastasis.
Research refines association between cardiovascular disease risk factors and prostate cancer, highlighting LDL cholesterol and triglycerides as key players. The study identifies 17 related gene loci that contribute to both high blood lipid levels and prostate cancer risk.
Researchers at Michigan Medicine have found that BET bromodomain protein 4 binds to the hormone androgen receptor, making it a potential target for prostate cancer treatment. The study suggests that a drug targeting this protein could work even when prostate cancer becomes resistant to current therapies.
A new study found that chronic inflammation in non-cancerous prostate tissue may increase a man's risk of developing high-grade prostate cancer by nearly twice. The study showed that men with signs of chronic inflammation had a higher risk of having an aggressive and rapidly growing prostate cancer.
A study found that chronic inflammation in benign prostate tissue was associated with high-grade prostate cancer. Men with at least one biopsy core showing inflammation had a 1.78 times higher odds of having prostate cancer and a 2.24 times higher odds of having aggressive disease.
A new method using existing ultrasound scanners allows doctors to accurately detect prostate cancer with much greater precision, reducing the need for painful biopsies. The technique saves money by eliminating costly biopsy analysis and can potentially eliminate biopsies altogether.
Researchers found that circumcised men were 45% less at risk of developing prostate cancer than uncircumcised men. The protective effect was strongest among black men, who were 60% less likely to develop the disease if circumcised after age 35.
A clinical trial found that six months of hormone therapy added to radiotherapy significantly reduces the risk of prostate cancer relapse and progression. Men who received both treatments had a nearly 50% lower risk of biochemical progression compared to those treated with radiotherapy alone.
Researchers develop a technique to trick prostate cancer cells into using more glucose for imaging via PET scans, reducing the need for repeated biopsies. This method has potential therapeutic applications by cutting off cancer cells' energy supply from lipids.
Researchers developed a genetic signature to identify men at high risk of prostate cancer recurrence after surgery or radiotherapy. The test uses DNA analysis from biopsy tissue and shows promise in predicting treatment failure with close to 80% accuracy.
A study found that permanent brachytherapy preserves erectile function in approximately 50% of prostate cancer patients, improving treatment outcomes. Researchers call for further training on discussing and assessing sexual side-effects of radiation treatment to ensure adequate patient information.
A recent study published in JAMA found that taking daily tadalafil did not prevent erectile dysfunction (ED) in men undergoing radiation therapy for prostate cancer. The study involved 242 men who received either tadalafil or a placebo, and showed no significant difference in ED prevention between the two groups.
New research by USC Norris Comprehensive Cancer Center scientists suggests that elevated CTC counts after chemotherapy indicate a higher risk of death, while reduced CTCs cut the risk in half. This study demonstrates CTCs as an important biomarker for cancer research and treatment.
QUT Professor Colleen Nelson leads an international team of researchers in developing new drugs and treatments for aggressive prostate cancer. The team aims to understand the impact of current treatments on metabolic dysfunction and patient wellbeing, with the goal of improving treatment outcomes.
A comprehensive study of over 15,000 men with localized prostate cancer found that primary androgen deprivation therapy does not extend survival. The treatment is associated with serious adverse events and mitigates against its use as a primary treatment option.
The number of PSA screenings performed by doctors declined significantly after the 2012 USPSTF recommendations, with a greater impact seen among urologists.
Researchers found that MicroRNA-34 can suppress prostate cancer when paired with p53, but not individually. The study used mice models and found that combined silencing of miR-34 and p53 led to uncontrolled stem cell growth and high levels of cancer.
Research from Umeå University and Memorial Sloan Kettering Cancer Center found that frequent PSA testing in areas with high incidence rates results in lower prostate cancer mortality. However, this is offset by increased risk of overtreatment, which can lead to side effects such as erectile dysfunction and urinary incontinence.
A new study by Yale University researchers found that a faster and less expensive form of radiotherapy for treating prostate cancer may come with a higher rate of urinary complications. Stereotactic body radiotherapy (SBRT) is a newer treatment option that can be completed in one to two weeks, compared to seven to nine weeks for intens...
A new approach to prostate cancer screening is needed, focusing on high-risk men rather than the entire population. The risk-based approach uses a computer-generated calculator that assesses factors like PSA levels, family history, and ethnicity to identify those at greatest risk.
Scientists at the University of Surrey have developed a new test to detect prostate and bladder cancers, showing twice the effectiveness of the existing PSA blood test. The EN2 biomarker test is being commercialized by Randox Laboratories and could lead to faster detection and cost savings.
A new study finds that radical prostatectomy reduces mortality in men under 65, while still benefiting older men by reducing metastases and treatment needs. The research used data from the Scandinavian Prostate Cancer Group Study Number 4, which randomized 695 men to surgery or watchful waiting with no initial treatment.
Researchers have found a link between prostate cancer aggressiveness and cholesteryl ester accumulation, suggesting new diagnostic and treatment methods. The study also shows that drugs previously developed to treat atherosclerosis might be repurposed for advanced prostate cancer treatment.
Patient satisfaction with treatment is greater when outcome information is specific to their treating physician, according to a study. This type of information helps patients set realistic expectations and make informed decisions about therapy selection.
Researchers found higher levels of BPA in prostate cancer patients than non-prostate cancer patients, with low-dose exposure linked to centrosome amplification and cell transformation. The study suggests a previously unknown relationship between BPA exposure and prostate cancer development.
The PROCEDE 500 study demonstrates that the Prolaris test provides personalized risk assessment for prostate cancer patients, leading to significant changes in treatment plans. The study found a 50% reduction in surgical interventions and a 30% reduction in radiation treatment.
A UCLA study published in European Urology found that robotic-assisted prostate surgery resulted in 5% fewer positive margins and a one-third reduction in the likelihood of needing additional cancer therapies. This suggests that robotic-assisted radical prostatectomy may offer better cancer control with potentially lower downstream costs.
University of Houston scientists identify AMPK enzyme's role in prostate cancer progression and metabolic changes. Their findings suggest that targeting metabolic pathways could lead to more effective cancer treatments.
The trial found that men treated with the more intensive radiotherapy regime had a 55% survival rate without disease progression, compared to 43%. The study also showed that dose-escalated radiotherapy reduces the need for follow-up hormone treatment and is safe in the long term.
A study published in the Journal of the National Cancer Institute found that high-dose supplementation with selenium and vitamin E increases the risk of high-grade prostate cancer in men. The risk depends on a man's baseline selenium level, with men who have low levels experiencing a higher risk
A new study published in JNCI Journal of the National Cancer Institute found that high-dose selenium supplementation increased the risk of high-grade prostate cancer among older men with high baseline toenail selenium concentrations. Vitamin E supplementation also raised PC risk, especially among men with low baseline selenium levels.
Scientists at The Institute of Cancer Research have discovered that screening for certain genetic mutations in men with a family history of prostate cancer can predict the development of aggressive forms of the disease. The study identified 13 'loss of function' mutations in eight DNA repair genes, which significantly increase the risk...
Researchers discovered that SPOP protein selectively destroys androgen receptor, a master regulator of prostate cancer cell growth. This finding sheds light on a new mechanism by which prostate cancer develops.
Scientists have discovered how the prostate gland develops for the first time, identifying 80 genes and a signalling pathway involved in its growth. The finding provides potential targets for new therapies to combat common prostate diseases, including prostate cancer.
A new study found that 3D mapping biopsies detect nearly three times as many cancerous zones in prostate cancer patients compared to ultrasound-guided biopsies. The study suggests that 3D mapping biopsies can accurately assess the location, stage, and risk of prostate cancer, leading to more targeted treatment options.
Dormant prostate cancer cells in bone tissue can be reactivated to form secondary tumors when exposed to the signaling molecule RANKL. Researchers have discovered that this reactivation process may lead to metastatic prostate cancer in bones, and targeting it could prevent metastasis and improve survival rates.
The PROCEDE 500 clinical utility study demonstrates the significant clinical value of Prolaris to physicians treating men with prostate cancer. The test accurately predicts prostate cancer-specific death and metastases, guiding treatment decisions and reducing therapeutic burden on patients.